NanoViricides President Dr. Anil Diwan praised the U.S. Food and Drug Administration's revised COVID-19 booster recommendations, which now target high-risk populations instead of broad public distribution. The new policy signals a significant shift in pandemic response strategies, focusing on evidence-based guidance and selective vaccination approaches.
Diwan emphasized that the limited booster uptake and increasing public immunity underscore the need for alternative medical interventions. The company views this policy change as an opportunity to advance its NV-387 antiviral drug, a broad-spectrum treatment designed to address respiratory viral infections including COVID-19, influenza, and respiratory syncytial virus (RSV).
The development-stage pharmaceutical company is currently preparing to advance NV-387 into Phase II human clinical trials. This drug candidate represents a potential complementary approach to vaccination, offering a treatment option that could reduce dependence on booster shots.
NanoViricides' strategy aligns with global health trends moving toward more targeted and personalized medical interventions. By developing specialized antiviral treatments, the company aims to provide flexible solutions for emerging and evolving viral threats.
